E-ISSN: 2619-9467

Contents    Cover    Publication Date: 06 Jun 2023
Year 2023 - Volume 33 - Issue 2

Open Access

Peer Reviewed

ORIGINAL RESEARCH
706 Viewed572 Downloaded

Variants of Fumarate Hydratase Gene in Uterine Disorders: A Clinical Trial

Full Text PDF  
JCOG. 2023;33(2):81-7
DOI: 10.5336/jcog.2022-94609
Article Language: EN
Copyright Ⓒ 2020 by Türkiye Klinikleri. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)
ABSTRACT
Objective: The dysregulation of metabolism is a hallmark of cancer. Enzymes of tricarboxylic acid (TCA) cycle have a key role in pathogenesis of carcinogenesis as oncometabolits. The variants in fumarate hydratase (FH) gene have been linked to sporadic tumors and familial tumor propensity. To asses the prevalence of variants in the FH gene in endometrial carcinoma (EC) and uterine leiomyomas (UL). Material and Methods: This prospective study included 58 patients with EC and 44 with UL. The FH gene variants were analyzed in the DNA samples collected from peripheral circulation. All exons of the FH gene were replicated by polymerase chain reaction utilizing specific primers including intron-exon boundaries and than was sequenced with Sanger method. Results: Only two variants were detected in two different patients. The c.927G>A (p.Pro309Pro) and c.63C>T (p.Ala21Ala) variants were observed in patients with UL, EC respectively. c.927G>A (p.Pro309=) and c.63C>T (p.Ala21=) are rare variants inside the overall population with allele frequency ranges of 0.02428, 0.000014 respectively. Conclusion: The contribution of variants in genes encoding the TCA cycle enzymes in tumor cells has provided understanding fundamental role on metabolic alterations in carcinogenesis. Further studies are needed to discover the novel tumor mutations and identify appropriate treatment.
REFERENCES:
  1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646-74. [Crossref]  [PubMed] 
  2. Fuhler GM, Eppinga H, Peppelenbosch MP. Fumarates and cancer. Trends Mol Med. 2017;23(1):3-5. [Crossref]  [PubMed] 
  3. Xiao M, Yang H, Xu W, Ma S, Lin H, Zhu H, et al. Inhibition of α-KG-dependent histone and DNA demethylases by fumarate and succinate that are accumulated in mutations of FH and SDH tumor suppressors. Genes Dev. 2012;26(12):1326-38. Erratum in: Genes Dev. 2015;29(8):887. [Crossref]  [PubMed]  [PMC] 
  4. Tomlinson IP, Alam NA, Rowan AJ, Barclay E, Jaeger EE, Kelsell D, et al; Multiple Leiomyoma Consortium. Germline mutations in FH predispose to dominantly inherited uterine fibroids, skin leiomyomata and papillary renal cell cancer. Nat Genet. 2002;30(4):406-10. [Crossref]  [PubMed] 
  5. Linehan WM, Rouault TA. Molecular pathways: fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer. Clin Cancer Res. 2013;19(13):3345-52. [Crossref]  [PubMed]  [PMC] 
  6. Gunnala V, Pereira N, Irani M, Lilienthal D, Pirog EC, Soslow R, et al. Novel fumarate hydratase mutation in siblings with early onset uterine leiomyomas and hereditary leiomyomatosis and renal cell cancer syndrome. Int J Gynecol Pathol. 2018;37(3):256-61. [Crossref]  [PubMed]  [PMC] 
  7. Frey MK, Worley MJ Jr, Heyman KP, Caputo TA. A case report of hereditary leiomyomatosis and renal cell cancer. Am J Obstet Gynecol. 2010;202(6):e8-9. [Crossref]  [PubMed] 
  8. Smit DL, Mensenkamp AR, Badeloe S, Breuning MH, Simon ME, van Spaendonck KY, et al. Hereditary leiomyomatosis and renal cell cancer in families referred for fumarate hydratase germline mutation analysis. Clin Genet. 2011;79(1):49-59. [Crossref]  [PubMed] 
  9. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49. [Crossref]  [PubMed] 
  10. Yen TT, Wang TL, Fader AN, Shih IM, Gaillard S. Molecular classification and emerging targeted therapy in endometrial cancer. Int J Gynecol Pathol. 2020;39(1):26-35. [Crossref]  [PubMed]  [PMC] 
  11. Sparic R, Mirkovic L, Malvasi A, Tinelli A. Epidemiology of uterine myomas: a review. Int J Fertil Steril. 2016;9(4):424-35. [PubMed]  [PMC] 
  12. Wheeler KC, Warr DJ, Warsetsky SI, Barmat LI. Novel fumarate hydratase mutation in a family with atypical uterine leiomyomas and hereditary leiomyomatosis and renal cell cancer. Fertil Steril. 2016;105(1):144-8. [Crossref]  [PubMed] 
  13. Zhao Z, Wang W, You Y, Zhu L, Feng F. Novel FH mutation associated with multiple uterine leiomyomas in Chinese siblings. Mol Genet Genomic Med. 2020;8(1):e1068. [Crossref]  [PubMed]  [PMC] 
  14. Warburg O. On the origin of cancer cells. Science. 1956;123(3191):309-14. [Crossref]  [PubMed] 
  15. Gonçalves E, Sciacovelli M, Costa ASH, Tran MGB, Johnson TI, Machado D, et al. Post-translational regulation of metabolism in fumarate hydratase deficient cancer cells. Metab Eng. 2018;45:149-57. [Crossref]  [PubMed]  [PMC] 
  16. Pezzuto A, Carico E. Role of HIF-1 in cancer progression: novel insights. a review. Curr Mol Med. 2018;18(6):343-51. [Crossref]  [PubMed] 
  17. Losman JA, Kaelin WG Jr. What a difference a hydroxyl makes: mutant IDH, (R)-2-hydroxyglutarate, and cancer. Genes Dev. 2013;27(8):836-52. [Crossref]  [PubMed]  [PMC] 
  18. Sciacovelli M, Frezza C. Oncometabolites: Unconventional triggers of oncogenic signalling cascades. Free Radic Biol Med. 2016;100:175-81. [Crossref]  [PubMed]  [PMC] 
  19. Schaefer IM, Hornick JL, Bovée JVMG. The role of metabolic enzymes in mesenchymal tumors and tumor syndromes: genetics, pathology, and molecular mechanisms. Lab Invest. 2018;98(4):414-26. [Crossref]  [PubMed] 
  20. Aissani B, Zhang K, Mensenkamp AR, Menko FH, Wiener HW. Fine mapping of the uterine leiomyoma locus on 1q43 close to a lncRNA in the RGS7-FH interval. Endocr Relat Cancer. 2015;22(4):633-43. [Crossref]  [PubMed]  [PMC] 
  21. Miettinen M, Felisiak-Golabek A, Wasag B, Chmara M, Wang Z, Butzow R, et al. Fumarase-deficient uterine leiomyomas: an immunohistochemical, molecular genetic, and clinicopathologic study of 86 cases. Am J Surg Pathol. 2016;40(12):1661-9. [Crossref]  [PubMed]  [PMC] 
  22. Harrison WJ, Andrici J, Maclean F, Madadi-Ghahan R, Farzin M, Sioson L, et al. Fumarate hydratase-deficient uterine leiomyomas occur in both the syndromic and sporadic settings. Am J Surg Pathol. 2016;40(5):599-607. [Crossref]  [PubMed]  [PMC] 
  23. Talhouk A, McAlpine JN. New classification of endometrial cancers: the development and potential applications of genomic-based classification in research and clinical care. Gynecol Oncol Res Pract. 2016;3:14. [Crossref]  [PubMed]  [PMC] 
  24. Ylisaukko-oja SK, Cybulski C, Lehtonen R, Kiuru M, Matyjasik J, Szyma-ska A, et al. Germline fumarate hydratase mutations in patients with ovarian mucinous cystadenoma. Eur J Hum Genet. 2006;14(7):880-3. [Crossref]  [PubMed] 
  25. Martínek P, Grossmann P, Hes O, Bouda J, Eret V, Frizzell N, et al. Genetic testing of leiomyoma tissue in women younger than 30 years old might provide an effective screening approach for the hereditary leiomyomatosis and renal cell cancer syndrome (HLRCC). Virchows Arch. 2015;467(2):185-91. [Crossref]  [PubMed] 
  26. Zhang L, Walsh MF, Jairam S, Mandelker D, Zhong Y, Kemel Y, et al. Fumarate hydratase FH c.1431_1433dupAAA (p.Lys477dup) variant is not associated with cancer including renal cell carcinoma. Hum Mutat. 2020;41(1):103-9. [Crossref]  [PubMed]  [PMC]